BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miyoshi T, Kataoka T, Asahi A, Maruyama T, Okada R, Uemae Y, Ohno T. A transient increase and subsequent sharp decrease of chemo-refractory liver-metastasized uterine cervical small cell carcinoma to autologous formalin-fixed tumor vaccine plus anti-PD-1 antibody. Clin Case Rep 2016;4:687-91. [PMID: 27386130 DOI: 10.1002/ccr3.596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Miyazaki T, Ishikawa E, Matsuda M, Akutsu H, Osuka S, Sakamoto N, Takano S, Yamamoto T, Tsuboi K, Matsumura A. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome. J Neurooncol 2017;133:277-85. [PMID: 28447277 DOI: 10.1007/s11060-017-2451-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
2 Kuranishi F, Imaoka Y, Sumi Y, Uemae Y, Yasuda-Kurihara H, Ishihara T, Miyazaki T, Ohno T. Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine. Int J Breast Cancer 2018;2018:4879406. [PMID: 29576883 DOI: 10.1155/2018/4879406] [Reference Citation Analysis]
3 Serkies K, Jassem J. Systemic therapy for cervical carcinoma - current status. Chin J Cancer Res 2018;30:209-21. [PMID: 29861606 DOI: 10.21147/j.issn.1000-9604.2018.02.04] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
4 Miyoshi T, Kataoka T, Asahi A, Maruyama T, Okada R, Uemae Y, Ohno T. A transient increase and subsequent sharp decrease of chemo-refractory liver-metastasized uterine cervical small cell carcinoma to autologous formalin-fixed tumor vaccine plus anti-PD-1 antibody. Clin Case Rep 2016;4:687-91. [PMID: 27386130 DOI: 10.1002/ccr3.596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ishikawa E, Yamamoto T, Matsumura A. Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy. Neurol Med Chir (Tokyo) 2017;57:321-30. [PMID: 28539528 DOI: 10.2176/nmc.nmc.ra.2016-0334] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
6 Lybaert L, Vermaelen K, De Geest BG, Nuhn L. Immunoengineering through cancer vaccines – A personalized and multi-step vaccine approach towards precise cancer immunity. Journal of Controlled Release 2018;289:125-45. [DOI: 10.1016/j.jconrel.2018.09.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
7 Collins JM, Redman JM, Gulley JL. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy. Expert Rev Vaccines 2018;17:697-705. [PMID: 30058393 DOI: 10.1080/14760584.2018.1506332] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]